About Chakra Biotech

Our mission is to build a portfolio of intellectual property assets related to
new therapeutics and animal models for CNS disorders.

Chakra Biotech is focused on the development of drugs for CNS disorders, currently a USD50 billion market opportunity. Established in 2001, Chakra Biotech brings together two key intellectual property assets:

A world-wide exclusive license to a US-patented mouse model (the chakragati mouse) for dopamine dysfunction, validated as a model for screening antipsychotic compounds
A world-wide exclusive license to a library of novel compounds covered by five patents

Our unique behavioral screening model and lead compounds provides a solid foundation for creating important new CNS therapeutics.

Management Team

Anthony Bishop, Chief Executive Officer
Anthony has a successful track record in managing drug development programs, outsourced development activities and developing Asian-based services opportunities in the global pharmaceutical industry. Prior to joining Chakra Biotech, Anthony was Associate Director of Business Development at Quintiles East Asia and Project Manager on a number of drug development programs at CSL Limited. Anthony holds a Degree in Medical Technology from the Queensland University of Technology and a postgraduate Diploma in Management from the Royal Melbourne Institute of Technology.

Dr. Anil K. Ratty, Chief Scientific Architect
Anil founded Chakra Biotech in 2001 and has been pivotal to the development of Chakra's assets. Previously, Anil served in various corporate and research positions: Regional Director with Fischer Scientific; life science researcher at Buffalo General Hospital (USA); Roswell Park Cancer Institute (USA); the Institute of Cellular and Molecular Biology (Singapore) and the Defense Medical Research Institute (Singapore). Anil holds a PhD in Biochemistry from the National University of Singapore.